Focus on cannabis and psychdelic sectors, small cap, micro cap and mid cap companies
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Found this last night, definitely checking out.
Yes and they can flip today for 50x as they already did last week. I gotta read over their last financial report and see if they're under any kinda lock. Good for them tho, I just don't see it anything major either way.
No, no problem at all. I just don't view it as a huge show of confidence or a major influence to long term PPS. I do wish it was me tho at that price! lol
Yeah he paid .01chf(0.011usd) for them lol. What a gamble on his part. That tranche of options were probably expiring soon. Wish it was me lol!
This "new" news isn't on Relief Therapeutics' site. Sounds like rehashed info.
https://relieftherapeutics.com/category/news/
The insider exercised his stock options. He purchased 3mm shares at 0.011usd. Good for him. Bad for us.
Exactly. Just wait for it. It's coming. Probably tomorrow. Then news and we're up.
Down another -20% today. ouch!
We've been following them pretty much everyday past four days. The only thing that skews us from them is news reports that come out after their session but during ours. Yesterday it was that German article at 6:30pm Swiss time. Today's it was the interview. I've got bids in the 0.20s - 0.30s. Down -15% so far today. May not hit today, but without a daily news development, they will eventually.
That interview was really good. Great info...PPS has reacted slightly but still trending down. I guess we'll need another interview tomorrow to stay afloat? 0.30s coming back until the next PR. Need my +100k shares please.
That could've been said yesterday or Friday too but the chart doesn't lie. Remove emotions and focus on chart TA. I'm not hating, I just want another load of cheap shares that I know are coming lolol.
It hit .36. That was the very top edge of the gap. lol yes I missed .30 - .35. Maybe tomorrow - Friday tho! I'm ready.
That's cool but I expected this to revisit the .30s gap since last week. I'm ready for it.
We started off copying the Swiss market but that PR released at around 6:30pm their time. So we saw that and it affected our market. Otherwise this woulda tested .20 like the Swiss market did. I'm ready to load .20s - .35s easy. But yeah, without surprise PRs or Trump talking tonight, pps will continue to slide.
Never happened. HOD was .59. Probably confused with another stock. Let's keep everything actual factual here.
Monday closed +11%
Tuesday closed -24%
Gonna need another PR tonight/tomorrow to stay afloat or it's another -20% days coming till DMC comments on ongoing trial. Gotta separate the product from the market. Be prepared for .30s! They want it(and so do I lol).
Thanks, you literally copy/pasted my own post back to me lol so trust me, I'm aware. With over 2.2bn shares we see this can move -30% - -50% in a morning. They will get those low .30s. Just be ready, I know I will!
So they tried to press into the gap between .30 - .35. Almost got it, got it to the top of the gap @ .36. They'll try again, either the rest of today like the Swiss chart or tomorrow.
Are you serious? lol Doubt they're having classes right now.
haha I hope so!
Data Monitoring Committee info! On July 16, the company said we'd get a scheduled data review in 4 weeks. That should be this week(hopefully)
https://relieftherapeutics.com/neurorx-and-relief-therapeutics-announce-data-monitoring-committee-determination-to-continue-phase-2-3-trial-of-rlf-100-for-critical-covid-19/
NeuroRx and Relief Therapeutics announce Data Monitoring Committee determination to continue phase 2/3 trial of RLF-100 for Critical COVID-19
by Relief Therapeutics | Jul 16, 2020
-With resurgent COVID-19, enrollment has accelerated in Miami, Houston, and Irvine
-Data Monitoring Committee determined that so far RLF-100 has generated no drug-related Serious Adverse Events or other safety concerns that would mandate stopping. The study is to continue until the next scheduled data review in four weeks.
Primary endpoint is established as “Alive and free of Respiratory Failure.”
Radnor, PA and Geneva July 16, 2020 – NeuroRx, Inc., in partnership with RELIEF THERAPEUTICS Holdings AG (OTC:RLFTF, SIX:RLF) today announced that the independent Data Monitoring Committee has reviewed the findings in the first 30 patients treated in Fast Track FDA trials of RLF-100 (Aviptadil) in patients with Critical COVID-19 with respiratory failure.
The study protocol enrolls patients with Critical COVID-19 and Respiratory Failure and randomly assigns them to intravenous RLF-100 or Placebo in the hopes of achieving remission from this most-serious stage of COVID-19. At the committee’s recommendation, the primary endpoint is changed to “alive and free of respiratory failure at 7-10 days.” This change in primary endpoint from mortality at 28 days is driven by the general decrease in mortality with advances in treatment for Critical COVID-19 and by initial observations in the clinical trial.
This first interim analysis was focused on verifying the apparent safety of the drug in the first 30 patients and the feasibility of the study to reach its endpoint. The committee determined that the study appeared capable of reaching a statistically significant endpoint within its 144 patient sample size and voted for the study to continue until its next scheduled evaluation in four weeks.
The committee is composed of Prof. Alfred Sommer, MD, MHS, Dean Emeritus of the Johns Hopkins Bloomberg School of Public Health, Prof. Rita Colwell, PhD, former Director of the National Science Foundation, and Congressman, Andy Harris, MD, MHS (MD District 1) a part time Professor of Anesthesia and Critical Care at Johns Hopkins School of Medicine.
RLF-100 (Aviptadil) received Fast Track designation from the US FDA for the treatment of Critical COVID-19 with respiratory failure. Aviptadil is a synthetic form of human Vasoactive Intestinal Peptide (VIP) which is known to protect the Alveolar Type II cell of the lung from many forms of injury. This cell is critical to transmission of oxygen to the blood and is the site of attack for the Coronavirus.
“This milestone represents the extraordinary effort of our partners and collaborators at the University of Miami, Houston Methodist Hospital, UC Irvine, and University of Louisville who gave 100% to providing patients with Critical COVID-19 a chance to benefit from a potentially life-saving drug. We thank the members of the Data Monitoring Committee for devoting their valuable time to performing this vital role in helping to evaluate the safety and effectiveness of RLF-100,” said Prof. Jonathan C Javitt, MD, MPH, CEO of NeuroRx and the National Study Chair.
Details of the study are posted on clinicaltrials.gov NCT04311697.
https://relieftherapeutics.com/fda-grants-expanded-access-protocol-to-rlf-100-aviptadil-for-respiratory-failure-in-covid-19/
FDA grants Expanded Access Protocol to RLF-100 (Aviptadil) for Respiratory Failure in COVID-19
by Relief Therapeutics | Jul 29, 2020
-Expanded access protocol, including for pregnant women, is becoming available to patients who are ineligible for enrollment in the FDA clinical trial of RLF-100,
-RLF-100, a patented formulation of Aviptadil, is currently in development by NeuroRx and RELIEF THERAPEUTICS Holding AG under Fast Track Designation, and recently obtained positive safety opinion from the data monitoring committee.
Geneva and Radnor, PA, July 29, 2020 – RELIEF THERAPEUTICS Holding AG (SIX:RLF, OTC:RLFTF) “Relief” and its U.S. partner, NeuroRx, Inc. today announced that FDA has granted an Expanded Access Protocol for treatment of Respiratory Failure in COVID-19 with RLF-100 (aviptadil), a synthetic form of Vasoactive Intestinal Peptide (VIP). The protocol makes treatment available to patients who have exhausted standard therapies and are not eligible for the current phase 2/3 trial of RLF-100 because of confounding medical conditions and specifically makes the treatment available to pregnant women. Although the drug remains under investigation, rapid recovery from respiratory failure in COVID-19 has been seen in patients treated under FDA Emergency Use authorization.[1]
The expanded access protocol may be viewed on www.clinicaltrials.gov NCT04453839. Physicians who wish to enroll their patients in the protocol must submit the protocol to their local investigational review board and file FDA form 1572 with NeuroRx, Inc. Further information may be obtained from expandedaccess@neurorxpharma.com.
“By granting this Expanded Access protocol, FDA has made a potentially lifesaving drug immediately available to critically ill patients who have no other available treatment,” said Dr. Jonathan C. Javitt, MD, MPH, NeuroRx’s CEO. “We thank the FDA’s pulmonary division for its rapid and proactive implementation of the Coronavirus Treatment Acceleration Program, and we aspire to demonstrate broad safety and efficacy for RLF-100 in our ongoing clinical trial.”
The SARS-CoV-2 coronavirus that causes COVID-19 attacks the body by entering the small population of Alveolar Type II cells in the lung.[2] Without Type II cells, the lung cannot transmit oxygen, which why the coronavirus causes acute respiratory failure. 50 years of scientific research demonstrates that VIP binds specifically to the Type II cell and protects that cell against cytokines (inflammatory molecules) and a wide array of toxic and infectious injuries.”[3]
https://relieftherapeutics.com/rlf-100-aviptadil-clinical-trial-showed-rapid-recovery-from-respiratory-failure-and-inhibition-of-coronavirus-replication-in-human-lung-cells/
RLF-100 (aviptadil) clinical trial showed rapid recovery from respiratory failure and inhibition of coronavirus replication in human lung cells
by Relief Therapeutics | Aug 3, 2020
-Rapid recovery of patients on ventilators and ECMO (extracorporeal membrane oxygenation) was seen in patients with severe medical comorbidities after three days of treatment with RLF-100 under FDA Emergency Use IND authorization at multiple clinical sites.
-RLF-100 is being developed as the first COVID therapeutic to block replication of the SARS-CoV-2 virus in human lung cells and monocytes
-RLF-100 is a patented formulation of aviptadil (synthetic human Vasoactive Intestinal Polypeptide VIP), which has been granted FDA Fast Track Designation, FDA emergency use IND authorization, and an expanded access protocol.
Radnor, PA and Geneva, CH, August 3, 2020 – NeuroRx, Inc. and Relief Therapeutics Holdings AG (SIX:RLF, OTC:RLFTF) “Relief” today announced that RLF-100 (aviptadil) showed rapid recovery from respiratory failure in the most critically ill patients with COVID-19. At the same time, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes.
RLF-100 has been granted Fast Track designation by FDA and is being developed as a Material Threat Medical Countermeasure in cooperation with the National Institutes of Health and other federal agencies. Further research will be conducted.
The first report of rapid clinical recovery under emergency use IND was posted by doctors from Houston Methodist Hospital. The report describes a 54-year-old man who developed COVID-19 while being treated for rejection of a double lung transplant and who came off a ventilator within four days.[1] Similar results were subsequently seen in more than 15 patients treated under emergency use IND and an FDA expanded access protocol which is open to patients too ill to be admitted to the ongoing Phase 2/3 FDA trial.
Patients with Critical COVID-19 were seen to have a rapid clearing of classic pneumonitis findings on x-ray, accompanied by an improvement in blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation.[2] clinicaltrials.gov NCT04311697.
The clinical findings may be based on evidence that VIP inhibits the replication of the SARS-CoV-2 virus in human lung cells and immune cells (monocytes). The work was reported by Brazilian researchers working in a level-4 biocontainment laboratory.[3] The same researchers reported a case-control study in which patients who survived being on ventilators for COVID-19 had significantly higher levels of VIP in their blood than those who died of respiratory failure.
“No other antiviral agent has demonstrated rapid recovery from viral infection and demonstrated laboratory inhibition of viral replication,” said Prof. Jonathan Javitt, CEO and Chairman of NeuroRx. “We are conducting placebo-controlled trials to see whether the observations made in the case-control and open-label studies will be confirmed for less ill patients with COVID-19-related respiratory failure. Our independent Data Monitoring Committee will be conducting an interim analysis of these data later this month.”
Not by name but it's implied. I think it's only a matter of time before he mentions this drug. Probably just waiting for the data committee to give the approval. His buddy Congressman Andy Harris is on the committee so...
thank you
haha thanks, that's it exactly verbatim. I was on the phone with someone, telling'em that when the secret service unholster their weapons, they're trained to take safeties off and be ready to shoot. You got it 100%
BUT RFL-100's on the tips of Trump's lips now lol. We should hear news soon. That data committee will be reviewing the IV trial this week.
I'm paraphrasing but Trump just said:
"we should have a vaccine before the end of the year and therapeutics very very soon. In fact, the therapeutics are what I'm really excited for. You go into a hospital and get a shot or an injection..."
He's gotta be talking about RLF-100.
RLF up 22% in Swiss premarket
No, someone tweet him the Fox Business interview. He might re-tweet it.
2 minutes in Swiss market +88%
Great news!!!!
We're moving up! looking good!
Yeah I saw that. The Post and Times articles got us the volume yesterday but we need TV media talking about this. Trump's reaching for any positive news and may mention this today and brag that his administration fast tracked this. Matter of time before he mentions this.
Even tho this was picked up by Reuters, the Times and the Post, none of the major mainstream media outlets have reported on it smh. I checked all the usual suspects last night and found nothing. Weird. So there's a pop coming when this starts getting reported more broadly.
hmm. Schwab is free for pennies? They have L2?
I dunno what you guys are talking about. I paid $6.95 to buy my shares yesterday. Never had to pay 50 bucks to trade pennies on TD.
"were working on some things...some really great things actually...I just ordered my administration to fast track..."FAST TRACK"...that's right folks, I said fast track...a treatment that's being used in Israel right now and showing GREAT results...I hear it's showing great great results. This could be the best treatment so far and we're really looking into this one."
Got in at .07 this morning. Looks very very promising.
Just wait till Trump gives his presser today at 5pm EST and talks this therapy up and it's benefits.
Looks like we have some support around .40-.41 usd. Double bottom at .40 so far. Looks good, just need more eyes on it and more access. Still hearing about people not even being able to find it.
Yes Kevin O'Leary is an early Mind Med investor. Hear his pitch from his own lips:
Kevin O'Leary talks MindMed and why he's invested in psychedelics
MMEDF for all US investors. Available on TD this morning.
For Scotch, I always go with brand, quality and taste. I never look at the alcohol proof. I don't know anyone that walks into a bar/store and says "give me your scotch with the highest alcohol content"(I did that when I was an immature teenager maybe)...Actually, you know the kinda people who solely care about alcohol content? - Winos. I guess that's what you think the common cannabis consumer closely resembles nowadays? Using your logic, drinking the cheapest strongest source of alcohol will always do. Other things like brand, quality, flavor and smell don't matter. But we do know for many people there are other factors involved(price, taste, quality). I also know there's not much difference in inebriation effects between liquor that's 69% proof and another that's 75%. And my comparisons wouldn't make any sense to you because you're most likely not a consumer. Non-consumers tend to think all THC is THC and therefore all cannabis products are the same and all users need the strongest "fix" lol.